Cantor Fitzgerald Comments on Pharvaris FY2025 Earnings

Pharvaris (NASDAQ:PHVS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Pharvaris in a research report issued to clients and investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings of ($3.31) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $28.00 price objective on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06.

Separately, JMP Securities boosted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a report on Friday, January 31st.

Pharvaris Price Performance

Shares of PHVS traded down $2.39 during midday trading on Thursday, reaching $16.28. The stock had a trading volume of 96,393 shares, compared to its average volume of 73,369. The firm's 50 day moving average price is $15.16 and its 200-day moving average price is $17.98. Pharvaris has a 52 week low of $11.51 and a 52 week high of $25.50. The company has a market capitalization of $851.02 million, a P/E ratio of -5.82 and a beta of -2.85.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Soleus Capital Management L.P. boosted its stake in Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after purchasing an additional 216,483 shares during the period. FMR LLC boosted its position in shares of Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after buying an additional 189,714 shares during the period. Octagon Capital Advisors LP grew its holdings in shares of Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after buying an additional 157,530 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock valued at $8,510,000 after buying an additional 118,408 shares during the period. Finally, Northern Trust Corp lifted its stake in Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after acquiring an additional 76,188 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.